ELUT earnings analysis
What we found in ELUT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Elutia reported second-quarter revenue of $2.427 million and EPS of $(0.17), missing consensus revenue of $2.9 million and EPS of $(0.15), although gross margin improved to 59.6%. Liquidity was supported by a $10 million initial senior secured loan and a potential $5 million delayed draw, but the financing carries interest of at least 12.25% and includes warrants for 1,395,348 shares. The planned SimpliDerm sale could provide up to $11 million, but closing and proceeds are uncertain, while the company faces a Nasdaq minimum-bid deficiency through February 2, 2027.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Gross margin improved
- Second-quarter revenue was $2.427 million and EPS was $(0.17), while gross margin improved to 59.6%.
- $10 million initial loan funded
- On August 11, 2026, the company received an initial $10 million senior secured term loan, with an additional $5 million delayed-draw tranche available subject to conditions.
- Potential SimpliDerm proceeds
- The SimpliDerm APA provides for aggregate consideration of up to $11 million, including $8 million in cash at closing, subject to adjustments and contingencies.
- Prior facility repayment reduced rate risk
- The company repaid its SWK Loan Facility on October 1, 2025 and reported no material interest-rate risk during the six months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- SimpliDerm sale may not close
- The SimpliDerm sale is subject to multiple closing conditions, and the company only expects completion in Q3 2026; there is no assurance the transaction will close on time or at all.
- Disposition proceeds are uncertain
- Although aggregate SimpliDerm consideration is up to $11 million, only $8 million is payable in cash at closing; up to $2 million of milestone payments and up to $1 million of earn-outs remain contingent.
- Major revenue transition risk
- SimpliDerm generated approximately 61% of aggregate revenue in the first six months of 2026 versus 81% in the first six months of 2025, creating material post-disposition revenue concentration and transition risk.
- Nasdaq minimum-bid deficiency
- Nasdaq notified the company that its closing bid price had been below $1.00 for 30 consecutive business days, with a compliance deadline of February 2, 2027; failure to regain compliance could result in delisting.
- Expensive secured financing
- The new term loans bear interest at the greater of 12.25% or the Wall Street Journal Prime Rate plus 5.50%, and are secured by substantially all company assets.
- Warrant and dilution risk
- The financing includes warrants exercisable for 1,395,348 shares at an exercise price capped by the lower of $0.86 and a potentially lower future offering price, creating dilution risk.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.17
- Gross margin
- 59.6%
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects the SimpliDerm Disposition to occur in Q3 2026, subject to closing conditions. The filing also states that the $5 million Second Tranche Term Loan may be available from May 1, 2027 through September 30, 2027, subject to regulatory approvals and liquidity conditions.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- Elutia Inc. reported Q1 2026 financials with revenue of $3.114 million, exceeding estimates of $3.0 million, though it posted an EPS loss of $-0.17, missing the expected $-0.15. Management expects to maintain gross…
- 10-K · March 13, 2026
- Elutia completed strategic portfolio divestitures in 2025 and is repositioning as a focused developer of drug-eluting biomatrix (DEB) products for reconstructive surgery. The company closed the sale of its CIED business…
- 10-Q · November 12, 2025
- Elutia reported Q3 2025 net sales of $3,323,000 and GAAP diluted loss per share of $(0.19). Gross margin expanded to ~55.8% while loss from operations narrowed to $(5,208,000) compared with $(9,175,000) in Q3 2024.…
- 10-Q · May 13, 2024
- Elutia reported Q1 net sales of $6,694,000 (up from $6,392,000 a year ago) but posted a larger net loss of $17,994,000 (net loss per share $0.75) driven by a $9,637,000 loss on revaluation of the warrant liability and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ELUT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever